Laos Lucius and Daxiong generic drugs cut prices, changing the competitive landscape of Sotolasibu market

The US Food and Drug Administration (FDA) has approved a drug with good efficacy, Sotorasib, for the treatment of patients with locally advanced or metastatic KRAS G12C mutation-positive non-small cell lung cancer (NSCLC) who have received ≥ 1 systemic therapy. This is a drug called a KRAS inhibitor, which stops cancer cells from multiplying by blocking the action of abnormal proteins. This helps stop or slow the spread of cancer cells. High hopes have been placed on the drug, which has been designated an orphan drug by the FDA for this purpose, requiring patients to be tested with an FDA-approved diagnostic test before taking the drug.

Recently, Laos Lucius Pharmaceuticals and Daxiong Pharmaceuticals have announced price reductions. Their generic sotolasibu has entered the market at a more affordable price, which has attracted widespread attention. This price reduction not only benefits patients, but also has a profound impact on the market competition pattern of sotorasibu. It is understood that the price of the generic sotoraxibu produced by Laos Lucius Pharmaceutical Factory with the specification of 120mg*56 tablets has dropped to more than 1,000 yuan per box. At the same time, Daxiong Pharmaceutical’s products of the same specification also made price adjustments, with the price per box dropping to more than 2,000 yuan. Although prices may change due to exchange rate fluctuations, this price reduction trend is already very obvious.

This price reduction not only makes the drug more affordable for more patients, but also makes the sotolasiib market more competitive. Original drug manufacturers are facing strong challenges from generic drug manufacturers and have to reconsider their pricing strategies and market strategies. At present, the price of Hong Kong original research versionsotorasibuspecifications120mg*240 tablets is around RMB 80,000, and the price of European original research version 120mg*240 tablets is more than RMB 40,000. For more information on overseas drug prices and related information, please consult Yaode Medical Consultant.